Page last updated: 2024-09-05

symmetric dimethylarginine and (3S,5S,6E)-7-[3-(4-fluorophenyl)-1-(propan-2-yl)-1H-indol-2-yl]-3,5-dihydroxyhept-6-enoic acid

symmetric dimethylarginine has been researched along with (3S,5S,6E)-7-[3-(4-fluorophenyl)-1-(propan-2-yl)-1H-indol-2-yl]-3,5-dihydroxyhept-6-enoic acid in 1 studies

Compound Research Comparison

Studies
(symmetric dimethylarginine)
Trials
(symmetric dimethylarginine)
Recent Studies (post-2010)
(symmetric dimethylarginine)
Studies
((3S,5S,6E)-7-[3-(4-fluorophenyl)-1-(propan-2-yl)-1H-indol-2-yl]-3,5-dihydroxyhept-6-enoic acid)
Trials
((3S,5S,6E)-7-[3-(4-fluorophenyl)-1-(propan-2-yl)-1H-indol-2-yl]-3,5-dihydroxyhept-6-enoic acid)
Recent Studies (post-2010) ((3S,5S,6E)-7-[3-(4-fluorophenyl)-1-(propan-2-yl)-1H-indol-2-yl]-3,5-dihydroxyhept-6-enoic acid)
428273141,459368396

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Abedini, S; Dahle, DO; Fellström, B; Holdaas, H; Holme, I; Jardine, A; März, W; Midtvedt, K; Mjøen, G; Pihlstrøm, H; Pilz, S1

Trials

1 trial(s) available for symmetric dimethylarginine and (3S,5S,6E)-7-[3-(4-fluorophenyl)-1-(propan-2-yl)-1H-indol-2-yl]-3,5-dihydroxyhept-6-enoic acid

ArticleYear
Symmetric dimethylarginine as predictor of graft loss and all-cause mortality in renal transplant recipients.
    Transplantation, 2014, Dec-15, Volume: 98, Issue:11

    Topics: Adult; Aged; Arginine; Biomarkers; Fatty Acids, Monounsaturated; Female; Fluvastatin; Follow-Up Studies; Graft Rejection; Humans; Indoles; Kidney; Kidney Transplantation; Male; Middle Aged; Multivariate Analysis; Proportional Hazards Models; Renal Insufficiency; Risk Factors; Time Factors; Transplant Recipients; Treatment Outcome

2014